Device Trial Radar · NCT06008080
Post-Market Clinical Follow Up Study With Navitor Valve
Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Sep 29, 2023
Primary completion
Jul 2027
Study completion Jun 2032
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- First posted
- Aug 23, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluation of the safety and performance of the Navitor TAVI System in a Global Study
Conditions
- Aortic Stenosis
Interventions
Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading SystemDevice
Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortality at 30 days post-TAVI procedureTime frame: 30 days post index procedure
- Moderate or greater paravalvular leak at 30 days post-TAVI procedureTime frame: 30 days post index procedure
Locations
50 sites in 11 countries. Site status is shown where the registry gives one.
Royal Adelaide Hospital
Adelaide, Australia · Recruiting
Royal Hobart Hospital
Hobart, Australia · Recruiting
The Alfred Hospital
Melbourne, Australia · Recruiting
47 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.